Flagship Pioneering and Quotient Therapeutics Announce Agreement to Identify Potential Novel Targets for the Treatment of Cardiovascular and Renal Diseases under Strategic Partnership with Pfizer
Flagship Pioneering and Quotient Therapeutics have announced a collaboration with Pfizer to identify potential novel targets for cardiovascular and renal diseases. This agreement, initiated under the strategic partnership between Flagship Pioneering and Pfizer, leverages Quotient's Somatic Genomics platform to analyze somatic mutations in diseased patient tissue.
The collaboration involves two research programs aimed at discovering and developing transformative therapies. Pioneering Medicines, Flagship's in-house drug discovery unit, will lead the strategic partnership with Pfizer. This initiative represents a significant milestone in the partnership and highlights the potential of collaboration to accelerate therapeutic innovation in addressing cardiovascular and renal diseases, which are leading causes of mortality and morbidity worldwide.
Flagship Pioneering e Quotient Therapeutics hanno annunciato una collaborazione con Pfizer per identificare potenziali nuovi target per le malattie cardiovascolari e renali. Questo accordo, avviato nell'ambito della partnership strategica tra Flagship Pioneering e Pfizer, sfrutta la piattaforma di Genomica Somatica di Quotient per analizzare le mutazioni somatiche nei tessuti dei pazienti malati.
La collaborazione comprende due programmi di ricerca mirati a scoprire e sviluppare terapie trasformative. Pioneering Medicines, l'unità interna di scoperta farmaci di Flagship, guiderà la partnership strategica con Pfizer. Questa iniziativa rappresenta una pietra miliare significativa nella collaborazione e mette in evidenza il potenziale del lavoro insieme per accelerare l'innovazione terapeutica nell'affrontare le malattie cardiovascolari e renali, che sono le principali cause di mortalità e morbilità a livello mondiale.
Flagship Pioneering y Quotient Therapeutics han anunciado una colaboración con Pfizer para identificar posibles nuevos objetivos para las enfermedades cardiovasculares y renales. Este acuerdo, iniciado en el marco de la asociación estratégica entre Flagship Pioneering y Pfizer, aprovecha la plataforma de Genómica Somática de Quotient para analizar las mutaciones somáticas en el tejido de pacientes enfermos.
La colaboración incluye dos programas de investigación destinados a descubrir y desarrollar terapias transformadoras. Pioneering Medicines, la unidad interna de descubrimiento de fármacos de Flagship, liderará la asociación estratégica con Pfizer. Esta iniciativa representa un hito significativo en la colaboración y destaca el potencial de trabajar juntos para acelerar la innovación terapéutica en el tratamiento de las enfermedades cardiovasculares y renales, que son las principales causas de mortalidad y morbilidad en todo el mundo.
Flagship Pioneering과 Quotient Therapeutics는 심혈관 및 신장 질환에 대한 잠재적 새로운 표적을 식별하기 위해 Pfizer와 협력한다고 발표했습니다. 이 협정은 Flagship Pioneering과 Pfizer 간의 전략적 파트너십의 일환으로 시작되었으며, Quotient의 체세포 유전체 플랫폼을 활용하여 질병 환자 조직에서 체세포 돌연변이를 분석합니다.
이 협력은 혁신적인 치료법을 발견하고 개발하기 위한 두 개의 연구 프로그램을 포함합니다. Flagship의 내부 약물 발견 유닛인 Pioneering Medicines가 Pfizer와의 전략적 파트너십을 이끌 것입니다. 이 이니셔티브는 파트너십에서 중요한 이정표를 나타내며, 심혈관 및 신장 질환에 대한 치료 혁신을 가속화하기 위한 협력의 잠재력을 강조합니다. 이러한 질환은 전 세계적으로 높은 사망 및 이환율의 주요 원인입니다.
Flagship Pioneering et Quotient Therapeutics ont annoncé une collaboration avec Pfizer pour identifier de nouvelles cibles potentielles pour les maladies cardiovasculaires et rénales. Cet accord, initié dans le cadre du partenariat stratégique entre Flagship Pioneering et Pfizer, exploite la plateforme de Génomique Somatique de Quotient pour analyser les mutations somatiques dans les tissus de patients malades.
La collaboration implique deux programmes de recherche visant à découvrir et développer des thérapies transformatrices. Pioneering Medicines, l'unité interne de découverte de médicaments de Flagship, dirigera ce partenariat stratégique avec Pfizer. Cette initiative représente une étape significative dans le partenariat et souligne le potentiel de la collaboration pour accélérer l'innovation thérapeutique dans la lutte contre les maladies cardiovasculaires et rénales, qui sont les principales causes de mortalité et de morbidité dans le monde.
Flagship Pioneering und Quotient Therapeutics haben eine Zusammenarbeit mit Pfizer angekündigt, um potenzielle neuartige Ziele für Herz-Kreislauf- und Nierenerkrankungen zu identifizieren. Diese Vereinbarung, die im Rahmen der strategischen Partnerschaft zwischen Flagship Pioneering und Pfizer initiiert wurde, nutzt Quotients somatische Genomik-Plattform, um somatische Mutationen in erkranktem Patientenmaterial zu analysieren.
Die Zusammenarbeit umfasst zwei Forschungsprogramme, die darauf abzielen, transformative Therapien zu entdecken und zu entwickeln. Pioneering Medicines, die interne Arzneimittelforschungsabteilung von Flagship, wird die strategische Partnerschaft mit Pfizer leiten. Diese Initiative stellt einen bedeutenden Meilenstein in der Partnerschaft dar und hebt das Potential der Zusammenarbeit hervor, therapeutische Innovationen zur Bekämpfung von Herz-Kreislauf- und Nierenerkrankungen zu beschleunigen, die weltweit zu den Hauptursachen für Mortalität und Morbidität zählen.
- Strategic partnership with Pfizer to accelerate drug discovery and development
- Utilization of Quotient's Somatic Genomics platform for novel target identification
- Focus on cardiovascular and renal diseases, major global health concerns
- Potential for transformative therapies in uncharted genetic territory
- None.
This collaboration between Quotient Therapeutics and Pfizer, facilitated by Flagship Pioneering, represents a significant step forward in cardiovascular and renal disease research. Quotient's Somatic Genomics platform offers a novel approach to identifying potential drug targets by analyzing somatic mutations in diseased tissues.
The focus on cardiovascular and renal diseases is particularly noteworthy, as these conditions remain leading causes of global mortality and morbidity. By exploring genetic diversity at the cellular level, this research has the potential to uncover previously unknown disease mechanisms and lead to more targeted therapies.
While the immediate impact on investors may be , the long-term implications could be substantial if this collaboration yields breakthrough discoveries. However, it's important to note that drug discovery is a lengthy and uncertain process and tangible results may take years to materialize.
This partnership demonstrates Pfizer's strategic investment in early-stage research, potentially diversifying its pipeline in the cardiovascular and renal disease areas. For Flagship Pioneering, this collaboration validates its platform-based approach to drug discovery and could lead to future revenue streams if successful targets are identified.
While financial details are not disclosed, such partnerships often involve upfront payments, research funding and potential milestone payments. For Pfizer shareholders, this represents a low-risk, high-reward strategy to access innovative technologies without significant upfront costs.
Investors should view this as a long-term investment in R&D, with potential returns likely years away. The collaboration's success could enhance Pfizer's competitive position in these therapeutic areas, but it's too early to quantify any financial impact.
Collaboration leverages Quotient's platform to identify somatic mutations in genes that modify the progression of cardiovascular and renal diseases
Quotient and Pioneering Medicines, Flagship's in-house drug development unit, will jointly conduct research activities
Agreement initiated under strategic partnership between Flagship Pioneering and Pfizer
Pioneering Medicines, Flagship's in house drug discovery and development unit, is responsible for leading the strategic partnership with Pfizer, including driving the exploration process to rapidly surface potential drug development programs built on Flagship's diverse bioplatforms and modalities. The Quotient agreement is the most recent program initiated under Flagship's strategic partnership with Pfizer announced in July 2023.
"Quotient's Somatic Genomics platform explores the extensive genetic diversity within the 30 trillion cells inside our body. This offers an incredibly rich and unchartered territory for drug discovery," said Jacob Rubens, Co-Founder and CEO of Quotient Therapeutics and Origination Partner at Flagship Pioneering. "These two research programs will deploy our unique platform capabilities to identify novel links between genes and cardiovascular or renal disease, which are leading causes of mortality and morbidity around the world."
"Our strategic alliance with Pfizer was driven by a shared ambition – to develop novel medicines for patients sooner," said Paul Biondi, Flagship Pioneering General Partner and President of Pioneering Medicines. "This exploration with Quotient not only represents another exciting milestone for the partnership, but also speaks to the transformative potential of partnership to accelerate therapeutic innovation."
"This strategic collaboration with Flagship provides an opportunity to explore early discovery work with Quotient's proprietary platform to potentially unlock new targets for cardiovascular and renal disease," said Bill Sessa, Ph.D., Chief Scientific Officer of the Internal Medicine Research Unit at Pfizer. "With our deep cardiometabolic heritage, we will continue to push the boundaries of research innovation to help address significant gaps in care that remain for these patients."
About Flagship Pioneering and Pioneering Medicines
Flagship Pioneering invents and builds bioplatform companies, each with the potential for multiple products that transform human health or sustainability. Since its launch in 2000, Flagship has originated and fostered more than 100 scientific ventures, resulting in more than
Pioneering Medicines, Flagship Pioneering's in house drug development unit, is dedicated to conceiving and developing a broad portfolio of life-changing treatments for patients built from Flagship's innovative platforms. Harnessing the drug development expertise of its team together with the power of Flagship's multiple scientific platforms, Pioneering Medicines explores and identifies new product concepts which are then advanced jointly with Flagship's bioplatform companies. Pioneering Medicines also partners with external collaborators to apply its unique approach to partners' R&D priorities. These Innovation Supply Chain Partnerships are highly co-creative strategic alliances that accelerate therapeutic innovation by bringing together partners spanning the full spectrum of drug discovery, development, and production. Pioneering Medicines' current partners include Novo Nordisk, Pfizer, and the Cystic Fibrosis Foundation.
About Quotient Therapeutics
Quotient Therapeutics is the first company to systematically study the genetic variation and evolution of the trillions of cells inside the human body. The company's Somatic Genomics platform reveals novel links between genes and disease across a broad range of therapeutic areas, enabling the discovery of transformative medicines intended to cure, prevent, or reverse disease. Founded by Flagship Pioneering in 2022, Quotient is backed by experts in the field of somatic genetics.
Media Contacts:
For Quotient - Kristin Politi, Ph.D.
LifeSci Communications
kpoliti@lifescicomms.com
For Flagship – Olivia Offner
Flagship Pioneering
ooffner@flagshippioneering.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/flagship-pioneering-and-quotient-therapeutics-announce-agreement-to-identify-potential-novel-targets-for-the-treatment-of-cardiovascular-and-renal-diseases-under-strategic-partnership-with-pfizer-302230763.html
SOURCE Flagship Pioneering
FAQ
What is the purpose of the collaboration between Flagship Pioneering, Quotient Therapeutics, and Pfizer?
How does Quotient Therapeutics' platform contribute to the research programs?
What role does Pioneering Medicines play in the collaboration with Pfizer?
When was the strategic partnership between Flagship Pioneering and Pfizer announced?
